Glenmark Pharmaceuticals launches Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials

/PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce it has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL)...

Related Keywords

Vijay Raghavan ,States Glenmark ,Instagram ,Prnewswire Glenmark Pharmaceuticals Inc ,Linkedin Glenmark Pharmaceuticals ,Tm National Sales Perspectives ,Business Development Portfolio ,Validus Pharmaceuticals ,Biosimilars Companies ,Glenmark Pharmaceuticals Ltd ,Pharmaceuticals Inc ,United States ,Bumetanide Injection ,Single Dose Vials ,Multi Dose Vials ,Senior Vice President ,Product Launch ,Pharmaceutical Sales ,Dow Jones Sustainability Index ,Glenmark Pharmaceuticals ,Sales Perspectives ,